The Warsaw, IN-based firm and one of the Top 100 Medtech Companies said Monday that it has signed a definitive agreement to acquire Ossis, a firm that specializes in personalized 3-D printed implants, as well as complex hip replacements, including second-time hip replacements and replacements involving bone tumors and trauma.
The two companies have worked together in the past. Back in July 2021, Zimmer Biomet signed an agreement with Ossis as the company’s Asia Pacific partner for patient-specific 3D-printed titanium hip joint replacements and other pelvic bone replacement surgery. The partnership was expanded to Europe, the Middle East, and Africa in December 2022.
"Combining OSSIS's more than 16 years of clinical experience and engineering expertise with Zimmer Biomet's extensive network across Asia Pacific, Europe, Middle East and Africa demonstrates our commitment to bring transformative med tech advancements to patients in need," said Sang Yi, Zimmer Biomet Asia Pacific Group President. "We are very pleased to partner with these patients and their physicians as we work toward our mission to alleviate pain and improve the quality of life for people around the world."
It should be noted Zimmer Biomet was one of the first medical device companies in 2023 to partake in M&A. In early January, the company announced it would acquire Embody in a deal valued at $275 million to help expand its sports medicine portfolio.
Norfolk, VA - based Embody has developed a portfolio of collagen-based biointegrative solutions to support healing in orthopedic soft tissue injuries – including the Tapestry biointegrative implant for tendon healing and Tapestry RC, one of the first arthroscopic implant systems for rotator cuff repair.